Cystic fibrosis specialist Vertex remains at loggerheads with HTAs in England and France over its product pricing, but hopes its triplet regimes can eventually break the impasse.
Vertex Pharmaceuticals Inc. said it remained at loggerheads with HTAs in England and France over product pricing, notably its cystic fibrosis drug Orkambi (ivacaftor/lumacaftor), but voiced optimism that some form of reimbursement solution could come once the merits of its eventual triple combination cystic fibrosis regimen become clear.
These were the key themes voiced on 30 April when the Boston-based specialty pharma released its first-quarter update, which analysts...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
